Search Results

Expansion of Ancora Heart’s CorCinch HFrEF Early Feasibility Study Approved by FDA

February 3, 2020—Ancora Heart, Inc. announced that the FDA has approved an expansion of enrollment in the company's early feasibility study (EFS) evaluating the AccuCinch ventricular repair system in patients with reduced ejection fraction heart failure (HFrEF).

Thoratec Begins Shield II United States Clinical Trial

September 8, 2015—Thoratec Corporation announced that it has begun enrollment in the SHIELD II United States clinical trial examining the HeartMate PHP (percutaneous heart pump) in patients undergoing high-risk percutaneous coronary intervention (PCI).

IDE Approved for Pivotal Study of Ancora Heart's AccuCinch Ventricular Restoration System

June 30, 2020—Ancora Heart, Inc. announced FDA approval of its investigational device exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the company's AccuCinch ventricular restoration system in patients with heart failure and reduced ejection fraction.

CORCINCH-HF Pivotal Trial of Ancora Heart’s AccuCinch Reaches Enrollment Milestone

June 23, 2025—Ancora Heart, Inc. announced that it has reached the first enrollment milestone of 250 patients in the prospective, randomized, open-label, multicenter, international CORCINCH-HF pivotal trial of the company’s AccuCinch transcatheter left ventricular restoration system.

CORCINCH-HF Pivotal Trial Begins for Ancora Heart’s AccuCinch System

January 28, 2021—Ancora Heart, Inc. announced enrollment of the first patient in the CORCINCH-HF pivotal trial, which is designed to evaluate the safety and efficacy of the AccuCinch ventricular restoration system in patients who have symptomatic heart failure (HF) with reduced ejection fraction.

Ancora Heart’s AccuCinch System Evaluated in Analysis of HFrEF Patients

March 22, 2023—Ancora Heart, Inc., which is developing a completely transcatheter device-based therapy to address heart failure (HF), announced that patients treated with the company’s investigational AccuCinch ventricular restoration system demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.

Ancora Heart’s AccuCinch Ventricular Restoration System Receives FDA Breakthrough Device Designation

July 12, 2022—Ancora Heart, Inc. announced that the FDA has granted Breakthrough Device designation to the company’s AccuCinch ventricular restoration system.